^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:pimasertib (AS703026) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

    Excerpt:
    ...- Subjects with measurable, histologically or cytologically confirmed, locally advanced or metastatic cutaneous melanoma (stage III c or M1ac) N-Ras mutated....
    Trial ID:
    EMR 200066-007
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Target Oncol
    Title:

    Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

    Published date:
    11/19/2020
    Excerpt:
    Results from this phase I study indicate that pimasertib has clinical activity in patients with locally advanced/metastatic melanoma, particularly BRAF- and NRAS-mutated tumors...
    DOI:
    10.1007/s11523-020-00767-1
    Trial ID:
    NCT00982865